For example, combining PD-1/PD-L1 antibodies with regorafenib: in the REGOMUNE study, combining regorafenib with avelumab for the treatment of MSS CRC patients demonstrated that this combination therapy can enhance anti-tumor immunity; in the REGOTORI study, the combination of regorafenib with toripalimab for the treatment of MSS mCRC showed efficacy but did not reach statistical significance. This evidence concerns the gene CD274 and colorectal carcinoma.